Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi?
The pharmacologic specificity of low-molecular-weight heparins (LMWHs) has enabled multiple attractive developments in the prophylaxis and treatment of arterial thrombosis. Their high antithrombotic potency associated with a potentially lower induced bleeding risk, the lack of platelet interaction, the prevention of myointimal hyperplasia, and the lower incidence of heparin-induced thrombocytopenia, are major advantages. New studies in cardiology and vascular surgery demonstrate a high efficacy for LMWHs associated with a low risk.
Samama
C M
CM
Département d'Anesthésie-Réanimation Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Combe
S
S
Ill
P
P
Barre
E
E
Dreux
S
S
Viars
P
P
D000925:Anticoagulants / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000517:prevention & control*; D006348:Cardiac Surgical Procedures / Q000379:methods; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight